Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — IMMUNIC, INC.

Accession: 0001493152-26-051543

Filed: 2026-11-13

Period: 2026-11-13

CIK: 0001280776

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001280776

0001280776

2026-11-13

2026-11-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): November 13, 2026

IMMUNIC,

INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-36201

56-2358443

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS

Employer

Identification

No.)

1200

Avenue of the Americas, Suite 200

New

York, NY

10036

USA

(Address

of principal executive offices)

Registrant’s

telephone number, including area code: (332) 255-9818

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of exchange on which registered

Common

Stock, par value $0.0001

IMUX

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).

Emerging

growth company ☐

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item

2.02. Results of Operations and Financial Condition

On

November 13, 2026, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit

99.1, announcing the Company’s financial results for the quarter ended September 30, 2026, and providing a corporate update (the

“Earnings Release”).

The

information contained in Item 2.02 of this Current Report on Form 8-K, including the Earnings Release, shall not be deemed “filed”

for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section

or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated

by reference into any of the Company’s filings with the Securities and Exchange Commission, except as shall be expressly set forth

by specific reference in any such filing.

Item

9.01. Financial Statements and Exhibits

Exhibit

Description

99.1

Press Release dated November 13, 2026.

104

Cover

Page to this Current Report on Form 8-K in Inline XBRL.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its

behalf by the undersigned, hereunto duly authorized.

Dated:

November 13, 2026

Immunic, Inc.

By:

/s/

Erik Lundgren

Erik

Lundgren

Chief

Executive Officer

EX-99.1

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Immunic,

Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

–

Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data

Expected in December 2026 –

–

Initiation of Phase 3 PROTECT-MS Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Ongoing, with First-Patient-Enrolled

Expected in the First Half of 2027 –

–

Executive Leadership Team Further Strengthened with Appointments of Chief Data and Digital Officer and Chief People Officer to Support

Regulatory and Commercial Readiness –

NEW

YORK, November 13, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development

of novel oral therapies for neurologic diseases, today reported financial results for the third quarter ended September 30, 2026, and

provided a corporate update.

“As

we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is

entering one of the most important periods in its history,” said Erik Lundgren, Chief Executive Officer of Immunic. “We are

evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding

and addressing the needs of people living with MS. We believe vidofludimus calcium has the potential to address mechanisms associated

with both the neurodegenerative and inflammatory drivers of the disease, which, if confirmed in our Phase 3 trials, could offer a differentiated

treatment option in MS. Subject to positive ENSURE results, we are preparing for a potential New Drug Application (NDA) submission in

relapsing MS, while we continue to advance our Phase 3 program in progressive MS.”

“We

were fortunate to present exciting data in four posters at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, which added

complementary clinical and mechanistic evidence supporting the potential of vidofludimus calcium to address existing unmet needs in MS,”

added Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic. “Further, our Phase 3 ENSURE trials in relapsing MS continue

to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission

should the results be positive. In parallel, the Phase 2 CALLIPER data along with the insights shared by leading MS experts at our two

recent R&D Days support the rational for our Phase 3 PROTECT-MS trial in progressive MS, with initiation ongoing and first-patient-enrolled

expected in the first half of 2027.”

Third

Quarter 2026 and Subsequent Highlights

● Ongoing

Phase 3 ENSURE Relapsing MS Program: Continued to execute the fully enrolled twin Phase

3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS, which randomized

1,121 and 1,100 patients, respectively, at more than 100 sites in 15 countries.

● Preparation

of Phase 3 Progressive MS Program: Continued initiation activities for the Phase 3 PROTECT-MS

trial in progressive MS, informed by the Phase 2 CALLIPER trial data.

● Hosted

Virtual Progressive MS R&D Day: On November 5, 2026, hosted a virtual R&D

day focused on progressive MS. Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University

of Toronto, and Maria Pia Sormani, Ph.D., University

of Genoa, Italy, joined Immunic’s management team to discuss the key unmet needs

in progressive MS and the persistent needs for innovative

approaches to the development of therapies that target novel mechanisms associated with neurodegeneration

and MS progression. The event highlighted the potential expansion opportunity for

vidofludimus calcium in progressive MS, including the clinical and scientific rationale supporting

Immunic’s plans to initiate a Phase 3 progressive MS trial. A replay is available on

the “Events and Presentations” section of Immunic’s website.

● New

Data Presented at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting: Presented

new clinical, biomarker and preclinical data for vidofludimus calcium across four poster

presentations at MSToronto2026, held October 21-23, 2026, in Toronto. Highlights included:

○ New

analyses of the Phase 2 CALLIPER trial in progressive MS showed that the favorable trends

on disability outcomes observed during the double-blind main treatment period appeared to

be maintained during the open-label extension (OLE) phase among participants who continued

vidofludimus calcium treatment. Because the OLE phase is not placebo-controlled and includes

only participants who elected to continue treatment, these results should be interpreted

with caution. Only 6.5% of patients discontinued through the January 27, 2026 data cutoff,

with a safety and tolerability profile that appeared consistent with that observed in the

double-blind period.

○ New

preclinical findings suggest that vidofludimus calcium promoted neuronal survival under apoptotic

stress conditions, an effect requiring Nurr1. Under these in vitro experimental conditions,

this Nurr-1 dependent pro-survival effect was not observed with teriflunomide, providing

preclinical evidence suggesting that it involves mechanisms beyond DHODH inhibition. The

clinical relevance of these findings has not been established.

○ An

exploratory CALLIPER analysis found that vidofludimus calcium reduced Epstein-Barr virus

(EBV)-specific T-cell receptor sequence matches versus placebo-treated patients, and, in

a post-hoc analysis across all patients, reductions in EBV-specific matches were associated

with improved Symbol Digit Modalities Test (SDMT) scores.

○ In

a post-hoc analysis applying two proposed novel statistical methods that integrate disability

worsening and improvement into a single statistical measure, progressive MS patients in CALLIPER

treated with vidofludimus calcium appeared more likely to have positive disability outcomes

compared to placebo. These methods have not been validated or accepted by regulatory authorities.

● Hosted

Virtual Relapsing MS R&D Day: On September 9, 2026, hosted a virtual R&D day

focused on relapsing MS, at which management discussed the potential of vidofludimus

calcium to address mechanisms associated with both neurodegenerative and inflammatory drivers

of MS and shared insights into how its differentiated approach could add to the evolving

treatment landscape in relapsing MS. MS experts Amit Bar-Or, M.D., FRCPC, Perelman School

of Medicine, University of Pennsylvania, and Stephen Krieger, M.D., FAAN, Icahn School of

Medicine, The Mount Sinai Hospital, provided expert perspectives on the MS patient journey,

current treatment paradigms and unmet medical needs. A replay is available on the “Events

and Presentations” section of Immunic’s website.

● Expansion

of Executive Leadership Team and Board of Directors:

○ Appointed

Jaa Roberson as Chief People Officer, effective October 19, 2026. In this newly created executive

role, Ms. Roberson leads Immunic’s global talent and organizational strategy as the

company prepares for the ENSURE read-out and potential commercialization. Ms. Roberson brings

more than two decades of human resources experience, most recently as Chief People Officer

at Day One Biopharmaceuticals, and earlier, at Genentech supporting commercial franchises,

including Ocrevus® for MS.

○ Appointed

Chitrang Davé, M.B.A., as Chief Data and Digital Officer, effective September 1, 2026.

In this newly created C-suite role, Mr. Davé leads Immunic’s enterprise-wide

data, analytics, AI and digital strategy in support of NDA and commercial readiness. Mr.

Davé brings more than 25 years of data and analytics leadership experience across

regulated life sciences environments, most recently as Head of Enterprise Data, AI &

Advanced Analytics at Avidity Biosciences, and previously in senior roles at Edwards Lifesciences

and Medtronic.

○ Appointed

Elena Ridloff, CFA, to the Board of Directors, effective August 6, 2026. Ms. Ridloff brings

more than 20 years of leadership experience in finance, corporate development, investor relations,

and capital markets across the biopharmaceutical industry. She currently serves as Chief

Financial Officer and Chief Business Officer at Sionna Therapeutics.

Anticipated

Clinical Milestones

● Vidofludimus

Calcium in Relapsing MS: Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials

remains on track and is expected to be available in December 2026. If positive, Immunic plans

to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval

date in 2028.

● Vidofludimus

Calcium in Progressive MS: The initiation of the Phase 3 PROTECT-MS trial in progressive

MS is ongoing, with first-patient-enrolled expected in the first half of 2027.

● IMU-381:

The IMU-381 program, selected to leverage the Nurr1 platform for neurologic and autoimmune

diseases, continues to be in preclinical testing with lead candidate identification ongoing.

Financial

and Operating Results

Total

Operating Expenses for the three and nine months ended September 30, 2026 were $43.4 million and $111.9 million, respectively. Included

in these results are $13.9 million and $25.2 million, respectively, of non-cash charges, primarily related to stock compensation expense.

Research

and Development (R&D) Expenses were $23.9 million for the three months ended September 30, 2026, as compared to $20.0 million

for the three months ended September 30, 2025. The $3.9 million increase reflects (i) a $1.9 million increase in personnel expenses,

$0.6 million of which was related to non-cash stock compensation, (ii) a $1.4 million increase for vidofludimus calcium drug supply,

(iii) a $2.9 million increase for NDA readiness activities, (iv) a $0.3 million increase due to drug-drug interaction studies in support

of a potential NDA filing and (v) a $0.2 million increase related to costs across numerous categories, partially offset by (vi) a $1.8

million decrease related to the ENSURE clinical trials and (vii) a $1.0 million decrease related to the CALLIPER clinical trial.

For

the nine months ended September 30, 2026, R&D expenses were $75.5 million, as compared to $62.9 million for the nine months ended

September 30, 2025. The $12.6 million increase reflects (i) a $7.4 million increase in personnel expenses, $4.4 million of which was

related to non-cash stock compensation, (ii) a $4.5 million increase for vidofludimus calcium drug supply, (iii) a $4.1 million increase

for NDA readiness activities, (iv) a $3.9 million increase due to drug-drug interaction studies in support of a potential NDA filing

and (v) a $1.7 million increase related to costs across numerous categories, partially offset by (vi) a $5.2 million decrease related

to the ENSURE clinical trials and (vii) a $3.8 million decrease related to the CALLIPER clinical trial.

General

and Administrative (G&A) Expenses were $19.4 million for the three months ended September 30, 2026, as compared to $6.0 million

for the same period ended September 30, 2025. The $13.4 million increase was due to (i) an $11.0 million increase related to personnel

expenses, of which $9.7 million was related to non-cash stock compensation primarily related to a separation agreement, (ii) a $1.3 million

increase in legal and consultancy expenses, (iii) a $0.6 million increase in pre-commercial marketing expenses and (iv) a $0.5 million

increase in related costs across numerous categories.

For

the nine months ended September 30, 2026, G&A expenses were $36.4 million, as compared to $17.0 million for the same period ended

September 30, 2025. The $19.4 million increase was due to (i) a $15.2 million increase related to personnel expenses, of which $13.2

million was related to non-cash stock compensation primarily related to a separation agreement, (ii) a $2.3 million increase in legal

and consultancy expenses, (iii) a $1.2 million increase in pre-commercial marketing expenses and (iv) a $0.7 million increase in related

costs across numerous categories.

Interest

Income was $1.1 million for the three months ended September 30, 2026, as compared to $0.4 million for the three months ended September

30, 2025. The $0.7 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement.

For

the nine months ended September 30, 2026, interest income was $3.1 million, as compared to $0.8 million for the same period ended September

30, 2025. The $2.3 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement.

Other

Income (Expense) was ($0.03 million) for the three months ended September 30, 2026, as compared to ($0.01 million) for the same period

ended September 30, 2025.

For

the nine months ended September 30, 2026, Other Income (Expense) was ($0.2 million), as compared to $1.2 million for the same period

ended September 30, 2025. The $1.4 million decrease was primarily attributable to (i) $1.0 million of grant income from the German Federal

Ministry of Finance recognized in the first quarter of 2025 and no grant income in 2026 and (ii) a $0.4 million decrease across various

categories.

Net

Loss for the three months ended September 30, 2026, was approximately $42.3 million, or $0.99 per basic and diluted share, based

on 42,797,370 weighted-average common shares outstanding, compared to a net loss of approximately $25.6 million, or $1.32 per basic and

diluted share, based on 19,389,776 weighted-average common shares outstanding for the same period ended September 30, 2025.

Net

loss for the nine months ended September 30, 2026, was approximately $109.0 million, or $2.83 per basic and diluted share, based on 38,508,964

weighted-average common shares outstanding, compared to a net loss of approximately $77.9 million, or $5.45 per basic and diluted share,

based on 14,281,149 weighted-average common shares outstanding for the same period ended September 30, 2025.

Cash

and Cash Equivalents as of September 30, 2026 were $132.0 million. Based on its current operating plan, Immunic expects that these

funds will be sufficient to fund its operations into late 2027.

About

Immunic, Inc.

Immunic,

Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.

The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently

being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026.

Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is ongoing, with first-patient-enrolled expected

in the first half of 2027. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1

(Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase

(DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building

a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Vidofludimus

calcium (IMU-838) is an investigational medicinal product that has not been approved or authorized by the U.S. Food and Drug Administration

(FDA), the European Medicines Agency (EMA), or any other regulatory authority for any indication in any jurisdiction. Its safety and

efficacy have not been established. Any clinical, biomarker, or preclinical findings described reflect investigational data and are not

intended to suggest that vidofludimus calcium is safe or effective for any use.

Cautionary

Statement Regarding Forward-Looking Statements

This

press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the

safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts,

included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses,

sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of

management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the nature,

strategy and focus of the company; the development and commercial potential of Immunic’s product candidates, including their potential

to safely and effectively target diseases; preclinical and clinical data for Immunic’s development programs; the expected timing

and results of the Phase 3 ENSURE trials; the timing of a Phase 3 trial of vidofludimus calcium in progressive multiple sclerosis; the

timing of potential NDA submission and regulatory approval; expectations regarding the capitalization, resources and ownership structure

of the company; the expected sufficiency of Immunic’s cash and cash equivalents; and the executive and board structure of the company.

Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking

statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s

current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those

projected in the forward-looking statements as a result of many factors, including, without limitation, the risk that top-line results

from the ENSURE-1 and ENSURE-2 trials may be delayed, negative, or fail to meet their primary or secondary endpoints; the risk that results

of earlier, post-hoc, exploratory, open-label or preclinical analyses may not be predictive of, or confirmed in, subsequent controlled

clinical trials or accepted by regulatory authorities; the risk that the initiation, or first-patient enrollment in, of the Phase 3 progressive

MS trial, or the submission or approval of an NDA, may be delayed or may not occur; risks related to drug development and the regulatory

review process; the risk that Immunic’s cash and cash equivalents may be insufficient to fund operations for the period anticipated,

including due to changes to its operating plan, and Immunic’s need to raise additional capital; increasing inflation, tariffs and

macroeconomic trends; impacts of the Ukraine – Russia conflict and the conflict in the Middle East on clinical trials; changes

to the size of the target markets for the company’s product candidates; the protection and market exclusivity provided by Immunic’s

intellectual property; and the impact of competitive products and technological changes. A further list and descriptions of these risks,

uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report

on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent

filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Copies of these filings are

available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the

date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances

that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken

based on any or all of the contents of this press release.

Contact

Information

Immunic,

Inc.

Jessica

Breu

Vice

President Investor Relations and Communications

+49

89 2080 477 09

jessica.breu@imux.com

US

IR Contact

LifeSci

Advisors

Joyce

Allaire

immunic@lifesciadvisors.com

US

Media Contact

Real

Chemistry

media@imux.com

Financials

Immunic,

Inc.

Condensed

Consolidated Balance Sheets

(In

thousands, except share and per share amounts)

(Unaudited)

September 30,

2026

December 31,

2025

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$ 131,963

$ 15,483

Other current assets and prepaid expenses

3,124

7,386

Total current assets

135,087

22,869

Property and equipment, net

832

608

Right-of-use assets, net

504

575

Total assets

$ 136,423

$ 24,052

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$ 10,120

$ 10,138

Accrued expenses

20,058

18,645

Other current liabilities

1,372

1,835

Total current liabilities

31,550

30,618

Long-term liabilities

Other long term liabilities

400

107

Total long-term liabilities

400

107

Total liabilities

31,950

30,725

Commitments and contingencies

Stockholders’ equity:

Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of September 30, 2026 and December 31, 2025

—

—

Common stock, $0.0001 par value; 500,000,000  authorized as of September 30, 2026 and December 31, 2025, and 15,880,822 and 12,038,263 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

1

1

Additional paid-in capital

819,290

599,249

Accumulated other comprehensive income

2,749

2,648

Accumulated deficit

(717,567 )

(608,571 )

Total stockholders’ equity

104,473

(6,673 )

Total liabilities and stockholders’ equity

$ 136,423

$ 24,052

Immunic,

Inc.

Condensed

Consolidated Statements of Operations

(In

thousands, except share and per share amounts)

(Unaudited)

Three Months

Ended September 30,

Nine Months

Ended September 30,

2026

2025

2026

2025

Operating expenses:

Research and development

$ 23,948

$ 20,012

$ 75,505

$ 62,914

General and administrative

19,421

5,981

36,426

16,987

Total operating expenses

43,369

25,993

111,931

79,901

Loss from operations

(43,369 )

(25,993 )

(111,931 )

(79,901 )

Other income (expense):

Interest income

1,093

419

3,139

843

Other  income (expense), net

(33 )

(5 )

(204 )

1,186

Total other income

1,060

414

2,935

2,029

Net loss

$ (42,309 )

$ (25,579 )

$ (108,996 )

$ (77,872 )

Net loss per share, basic and diluted

$ (0.99 )

$ (1.32 )

$ (2.83 )

$ (5.45 )

Weighted-average common shares outstanding, basic and diluted

42,797,370

19,389,776

38,508,964

14,281,149

GRAPHIC

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (3195 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Nov. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Nov. 13, 2026

Entity File Number

001-36201

Entity Registrant Name

IMMUNIC,

INC.

Entity Central Index Key

0001280776

Entity Tax Identification Number

56-2358443

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

1200

Avenue of the Americas

Entity Address, Address Line Two

Suite 200

Entity Address, City or Town

New

York

Entity Address, State or Province

NY

Entity Address, Country

US

Entity Address, Postal Zip Code

10036

City Area Code

(332)

Local Phone Number

255-9818

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001

Trading Symbol

IMUX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration